At the Healey Center, we are working hard to provide people with ALS with access to potentially beneficial therapies.
This commitment includes providing access to investigational therapies for treatment through the Food and Drug Administration (FDA)-regulated Expanded Access Programs (EAPs). Drugs available through EAPs are potential therapies that hold promise but have yet been proven to show benefit. Information gathered through patient participation in these studies can accelerate testing and reduce the time it takes to get the most effective drugs to patients broadly.
We are building a dedicated team of Healey Center staff to rapidly implement EAPs for people with ALS at Mass General. This allows us to work efficiently with drug companies and regulatory agencies to provide people with ALS access to clinical trial drugs even when they don’t qualify for a formal trial. We are already working with several companies and are in discussions with more. Each EAP may enroll only a limited number of participants, and our goal is to expand to numerous EAP programs to best meet the needs of people with ALS.
Our ability to create EAP opportunities for the most promising therapies requires funding to build the infrastructure and staff to make this process effective. To ensure we can consistently oversee two EAPs each year, we are eager to raise funds to endow the program and provide a reliable revenue stream. Your support makes this work possible.
Thank you for partnering with us to accelerate the drive to the cure for ALS.
